Life sciences venture firm OrbiMed Advisors is raising capital for a $300 million investment fund based in Israel, according to a regulatory filing.
The firm isn’t currently commenting on the new fund, OrbiMed Partner Carter Neild said in an email. However, Israeli business publication Globes first wrote about OrbiMed’s early plans for a second fund back in April – when at the time the fund’s goal was some $250 million.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Globes viewed an OrbiMed presentation which, last April, appeared to be in preparation for the second fund. It said it plans to invest $5 million to $20 million in each of 12 to 15 companies – much like the first fund.
OrbiMed’s first Israeli fund closed in 2011, having raised $251 million. It coupled $203 million in private funding with another $48 million from the state. The fund invested $130 million in 19 Israeli companies, Globes reported – with an internal rate of return on its investments in Israel of 21.4 percent.
OrbiMed Israel currently has nine startups in its portfolio, ranging in focus from immunotherapy to endoscopic devices to healthcare analytics.
Notably, OrbiMed helped launch a medtech incubator in Israel last year, partnering with Johnson & Johnson and Takeda Pharmaceuticals.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
